Versor Investments LP Boosts Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Versor Investments LP boosted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 80.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,591 shares of the medical equipment provider’s stock after purchasing an additional 2,496 shares during the period. Versor Investments LP’s holdings in Lantheus were worth $614,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Janney Montgomery Scott LLC boosted its holdings in Lantheus by 10.0% during the 1st quarter. Janney Montgomery Scott LLC now owns 8,804 shares of the medical equipment provider’s stock valued at $548,000 after acquiring an additional 799 shares during the period. Envestnet Portfolio Solutions Inc. grew its holdings in shares of Lantheus by 9.0% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 5,369 shares of the medical equipment provider’s stock worth $334,000 after purchasing an additional 442 shares during the last quarter. Headlands Technologies LLC purchased a new position in Lantheus in the 1st quarter worth about $105,000. Russell Investments Group Ltd. lifted its holdings in Lantheus by 10.4% during the 1st quarter. Russell Investments Group Ltd. now owns 37,708 shares of the medical equipment provider’s stock valued at $2,347,000 after buying an additional 3,560 shares in the last quarter. Finally, ProShare Advisors LLC boosted its position in Lantheus by 4.7% in the 1st quarter. ProShare Advisors LLC now owns 15,567 shares of the medical equipment provider’s stock valued at $969,000 after buying an additional 698 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LNTH. JMP Securities decreased their price target on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a report on Friday, November 8th. Redburn Atlantic assumed coverage on Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. B. Riley upped their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Finally, Truist Financial reiterated a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $122.50.

Lantheus Stock Performance

LNTH stock opened at $79.76 on Thursday. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The firm has a market cap of $5.55 billion, a price-to-earnings ratio of 13.27 and a beta of 0.51. The firm has a 50-day simple moving average of $105.95 and a two-hundred day simple moving average of $96.28.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.